Published in AIDS Weekly, October 16th, 2000
Their research focuses on cachexia, an important syndrome they say doctors know well but which is largely unfamiliar to lay people, and could lead to an effective treatment for the condition.
Cachexia, which kills an estimated one-third of cancer patients, results from activation of a factor known as NF-kappa B, the new experiments show. NF-kappa B, a natural substance that attaches to DNA inside cell nuclei and turns genes...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2000-10-16)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.